The current study was designed to validate the potential and ability of a flavonoid compound (Dosiflavone), obtained from Dodonaea viscosa, as an anti-inflammatory, antipyretic, and analgesic along with in vivo acute toxicity in the animal model. different techniques such as xylene induced ear edema model, Carrageenan induced paw edema model, Hot plate pain model, Ethanoic acid-induced pain model, Yeast instigated pyrexia model acute toxicity model was used to investigate Dosiflavone. Dosiflavone showed significant (p<0.05) reduction of the ear edema at a high dose. However, at 20 mg/kg for 60 minutes, the impact was less important. In vivo anti-inflammatory testing revealed that Dosiflavone significantly (p<0.05) reduced the biphasic inflammatory events caused by carrageenan in a dose-dependent way, with the highest levels at 40 and 80 mg/kg. Dosiflavone showed excellent (p<0.05) analgesic activity with anti-nociceptive effect in hot plate test in a dose-dependent manner. Dosiflavone showed significant anti-nociceptive activity and decreased the number of writhes instigated by one % ethanoic acid. Dosiflavone dosages (20, 40, and 80 mg/kg) were relative to the placebo, there was a substantial (p<0.05-0.01) reduction in pyrexia. The Dosiflavone-treated and control groups showed no significant diferences in terms of mortality. As a result, it was determined that Dosiflavone is healthy in terms of mortality rate (up to 300 mg/kg). It is concluded that Dosiflavone has promising anti-inflammatory, anti-pyretic, and analgesic activity along with no toxicity at the higher dose. It is considered safe, however, needs further lead optimization through computational predictions, and using suitable animal models to address its pharmacokinetic behaviour and to improve its therapeutic efficacy and potency by enhancing its binding afinity against multiple target proteins. It must also be screened for longterm toxicological and side effects to further investigate its safety profile.